OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network’s OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, in T-Cell Acute Lymphocytic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) TAIPEI, Taiwan, April 26, 2021  — OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S.-based SWOG Cancer Research Network has started patient […]

This article is password protected.

To view the content, please enter your password in the field below